Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-C: Neoadjuvant Pembrolizumab in dMMR Colon Cancer
NCT05662527Phase 2Completed
- Start
- Feb 2023
- Primary completion
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in colon cancer. Primary endpoint: Pathological Complete Response. Started Feb 2023; status: completed.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05662527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05662527.